1. Home
  2. LTRN vs RGNT Comparison

LTRN vs RGNT Comparison

Compare LTRN & RGNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantern Pharma Inc.

LTRN

Lantern Pharma Inc.

HOLD

Current Price

$2.15

Market Cap

22.2M

Sector

Health Care

ML Signal

HOLD

RGNT

Regentis Biomaterials Ltd. Ordinary Shares

N/A

Current Price

$2.90

Market Cap

20.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LTRN
RGNT
Founded
2013
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.2M
20.4M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
LTRN
RGNT
Price
$2.15
$2.90
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
315.7K
3.1K
Earning Date
05-14-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
18.65
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.11
$2.73
52 Week High
$5.74
$8.35

Technical Indicators

Market Signals
Indicator
LTRN
RGNT
Relative Strength Index (RSI) 45.48 35.85
Support Level $1.11 $2.80
Resistance Level $2.41 $3.35
Average True Range (ATR) 0.32 0.16
MACD -0.03 0.02
Stochastic Oscillator 15.12 28.83

Price Performance

Historical Comparison
LTRN
RGNT

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.

About RGNT Regentis Biomaterials Ltd. Ordinary Shares

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

Share on Social Networks: